BackImpel Pharmaceuticals Overview

Impel Pharmaceuticals Cost of Revenue

Cost of Revenue analysis for IMPL.

Quarterly Cost of Revenue

$2.23M
47.88% YoY

As of Sep 30, 2023

Annual Cost of Revenue (TTM)

$9.95M
110.89% YoY

Trailing 12 months ending Sep 30, 2023

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)